- Video Gallery
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE AAA Research Reports
Editor Note: For more information about this release, please scroll to bottom.
LONDON, January 8, 2014 /PRNewswire/ --
On Tuesday, January 07, 2014, the U.S. equity market finished on a positive note. The S&P 500 ended the day at 1,837.88, up 0.61%; the Dow Jones Industrial Average closed at 16,530.94, up 0.64%; and the NASDAQ Composite Index finished at 4,153.18, up 0.96%. The S&P 500 Health Care Sector Index gained 1.01% to close the session at 644.13; and the S&P 500 Biotechnology Industry Index closed at 2,766.71, up 0.72%. The S&P 500 Biotechnology Industry Index has gained 10.05% in the previous three months, outperforming the S&P 500, which has gained 9.65% during the same period. Additionally, the S&P 500 Pharmaceuticals Sub Industry Index closed at 491.51, up 0.94%. The major movers in the Health Care Sector included Theravance Inc. (NASDAQ: THRX), Alkermes PLC (NASDAQ: ALKS), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and TherapeuticsMD Inc. (NYSE MKT: TXMD). All these companies are tracked by AAAResearchReports.com. Free technical research on THRX, ALKS, CBST, and TXMD can be downloaded upon signing up at:
Theravance Inc.'s stock rose 1.42% on Tuesday, tracking gains in the US equity market. The company's shares ended the day at $36.32, after oscillating between $35.59 and $36.53 during the trading session. A total of 0.83 million shares were traded, which is below the daily average volume 0.92 million. The company's shares have gained 0.06% in the previous three trading sessions, underperforming the S&P 500, which has gained 0.32% during the same period. However, Theravance Inc.'s stock is trading above its 50-day and 200-day moving averages of $36.02 and $35.62, respectively. Sign up and read the complimentary report on THRX at:
Shares in Alkermes PLC closed the day at $40.46, 0.59%, after fluctuating between $39.99 and $41.07 during Tuesday's trading session. A total of 0.94 million shares were traded, which is above the daily average volume of 0.89 million. Despite Tuesday's decline, the company's shares have gained 0.55% in the previous three trading sessions and 27.67% in the last three months, outperforming the S&P 500, which has gained 0.32% and 9.65% during the respective periods. Moreover, Alkermes PLC's stock is trading above its 50-day and 200-day moving averages of $38.58 and $32.75, respectively. The free report on ALKS can be downloaded by signing up now at:
Cubist Pharmaceuticals Inc.'s stock posted gains on Tuesday, finishing the day 1.06% higher from the previous day's closing price of $67.20. The company's shares vacillated between $67.00 and $68.50, before closing the day at $67.91. A total of 0.59 million shares were traded, which is below the daily average volume of 1.11 million. Cubist Pharmaceuticals Inc.'s shares have advanced 4.25% in the previous one month, outperforming the S&P 500, which has gained 1.82% during the same period. Furthermore, the company's stock is trading above its 50-day and 200-day moving averages of $64.95 and $57.96, respectively. A free report on CBST can be accessed by registering at:
TherapeuticsMD Inc.'s stock advanced 0.59% on Tuesday, finishing the day at $5.08, after fluctuating between $4.86 and $5.20 during the trading session. A total of 0.15 million shares were traded, which is below the daily average volume of 0.40 million. The company's shares have gained 7.86% in the previous one month and 42.70% in the previous three months, outperforming the S&P 500, which has gained 1.82% and 9.65% during the respective periods. Further, TherapeuticsMD Inc.'s stock is trading above its 50-day and 200-day moving averages of $4.60 and $3.11, respectively. Register with AAA Research Reports and download research on TXMD for free at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.